Text Size

Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by Centre Hospitalier Universitaire de Nice.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT01089465
First received: March 12, 2010
Last updated: December 7, 2011
Last verified: March 2010
History of Changes
  Purpose

During the last years, the investigators were the witness to the increase of a old emerging pest due to bed bugs (Cimex lectularius) in the world. Insecticides resistances apparitions and internationals transports increases seem to be the reasons of the pest. Cimex lectularius as vector of parasites, bacteria or virus was often suggested although not much observation are recently investigated in France. This study intends to examine the vectorial ability and the direct pathogenicity of Cimex lectularius.


Condition Intervention
Sting
 Other: Collection of the bedbugs and dermatological follow-up of the stings

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role

Resource links provided by NLM:

MedlinePlus related topics: Bedbugs
U.S. FDA Resources

Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:
  • Morphological identification of every bedbug Porterage of bacterial agents Porterage of viral agents Biomolecular identification of the insect A breeding of bedbugs Tests of sensibility in insecticides [ Time Frame: day 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Study of the direct pathogenicity of lectularius C. [ Time Frame: day 1, 7, 15 and 30 ] [ Designated as safety issue: No ]
    During each of four consultations a questionnaire and a descriptive index card(form) of the general and dermatological signs will be informed. The criteria of evaluation, associated with anonimisées photos, are split into two groups: general Signs and dermatological Signs


Estimated Enrollment: 135
Study Start Date: March 2010
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Collection of the bedbugs and dermatological follow-up of the stings
    Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • On the site of takings presence of insects and eggs evoking bedbugs of beds. The identification of certainty will be made in the laboratory. All the insects not apartment to the family of Cimicidae (Criterion of exclusion) are thrown(cast) in trash cans of laboratories for organic products.
  • voluntary Patients after reading of the information sheet and the signature of the consent
  • Membership of the patient in the national insurance scheme

Exclusion Criteria

  • On the site of takings absence of insects and eggs evoking bedbugs of beds
  • During the identification of certainty in the laboratory, the captured insects do not make parties of the family of Cimicidae
  • The subjects deprived of freedom.
  • Patients cancelling their consent.
  • Patients violating the protocol of search(research)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01089465

Contacts
Contact: Pascal Delaunay, PH 04.92.03.62.54 delaunay.p@chu-nice.fr

Locations
France
Collection of the bedbugs and dermatological follow-up of the stings Recruiting
Nice, France, 06000
Contact: Pascal Delaunay, PH     04.92.03.62.54     delaunay.p@chu-nice.fr    
Principal Investigator: Pascal Dr Delaunay, PH            
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Investigators
Principal Investigator: Pascal Delaunay, Dr CHU de Nice
  More Information

No publications provided

Responsible Party: Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier: NCT01089465     History of Changes
Other Study ID Numbers: 09-API-01
Study First Received: March 12, 2010
Last Updated: December 7, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Centre Hospitalier Universitaire de Nice:
Bed bugs
Cimex
insects
bites

Additional relevant MeSH terms:
Bites and Stings
Poisoning
Substance-Related Disorders
Wounds and Injuries

ClinicalTrials.gov processed this record on May 19, 2013